Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nous-209 vaccine plus pembrolizumab in MSI-H/dMMR colorectal cancer
2021-002823-40Phase 2Active
- Sponsor
- Nouscom
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NOUS-209 and pembrolizumab in colorectal cancer (CRC) and microsatellite unstable colorectal cancer, sponsored by Nouscom. Primary endpoint: Objective response rate at 12 months. Started Aug 2021; status: active.
02
Drugs
NOUS-209pembrolizumab
03
Conditions
colorectal cancer (CRC)microsatellite unstable colorectal cancer
Beyond the preview
Go deeper on 2021-002823-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002823-40.